Phase II study of glofitamab in patients with R/R LBCL

Phase II study of glofitamab in patients with R/R LBCL

Michael Dickinson, MBBS, DMedSc, on a Phase II Trial of Glofitamab in DLBCLПодробнее

Michael Dickinson, MBBS, DMedSc, on a Phase II Trial of Glofitamab in DLBCL

Phase II study of epcoritamab in R/R LBCLПодробнее

Phase II study of epcoritamab in R/R LBCL

Glofitamab plus R-CHOP in patients with high-risk LBCL: a Phase II trialПодробнее

Glofitamab plus R-CHOP in patients with high-risk LBCL: a Phase II trial

Phase I study of costimulatory bispecific antibody RO7227166 combined with glofitamab in R/R B-NHLПодробнее

Phase I study of costimulatory bispecific antibody RO7227166 combined with glofitamab in R/R B-NHL

Glofitamab as a single agent in heavily pretreated patients with DLBCLПодробнее

Glofitamab as a single agent in heavily pretreated patients with DLBCL

A Phase I/II trial of glofitamab monotherapy in R/R MCLПодробнее

A Phase I/II trial of glofitamab monotherapy in R/R MCL

Update on Phase I/II study of glofitamab monotherapy in R/R MCLПодробнее

Update on Phase I/II study of glofitamab monotherapy in R/R MCL

Insights into Phase I/II study assessing fixed-duration glofitamab treatment for R/R LBCLПодробнее

Insights into Phase I/II study assessing fixed-duration glofitamab treatment for R/R LBCL

Updated results of glofitamab plus polatuzumab vedotin combination therapy in DLBCL, including HGBCLПодробнее

Updated results of glofitamab plus polatuzumab vedotin combination therapy in DLBCL, including HGBCL

The current and future role of bispecifics in R/R DLBCL: epcoritamab, glofitamab & moreПодробнее

The current and future role of bispecifics in R/R DLBCL: epcoritamab, glofitamab & more

What is the rationale behind step-up dosing of glofitamab in patients with MCL?Подробнее

What is the rationale behind step-up dosing of glofitamab in patients with MCL?

Glofitamab: a valuable agent for the treatment of patients with R/R mantle cell lymphomaПодробнее

Glofitamab: a valuable agent for the treatment of patients with R/R mantle cell lymphoma

New DLBCL Clinical Trial: Epcoritamab for Diffuse Large B-Cell LymphomaПодробнее

New DLBCL Clinical Trial: Epcoritamab for Diffuse Large B-Cell Lymphoma

Glofitamab as a SOC in third-line DLBCL and its potential in earlier lines of therapyПодробнее

Glofitamab as a SOC in third-line DLBCL and its potential in earlier lines of therapy

Michael Dickinson, MBBS, DMedSc, on a Phase Ib Trial of Glofitamab Plus Pola-R-CHP in DLBCLПодробнее

Michael Dickinson, MBBS, DMedSc, on a Phase Ib Trial of Glofitamab Plus Pola-R-CHP in DLBCL

Phase II study of acalabrutinib plus RICE in R/R DLBCLПодробнее

Phase II study of acalabrutinib plus RICE in R/R DLBCL

Impact of TMTV on PFS following glofitamab treatment in R/R DLBCLПодробнее

Impact of TMTV on PFS following glofitamab treatment in R/R DLBCL

Extended follow-up of glofitamab monotherapy in R/R LBCL: durability of CR and likelihood of CRSПодробнее

Extended follow-up of glofitamab monotherapy in R/R LBCL: durability of CR and likelihood of CRS

The benefits of glofitamab in R/R DLBCL post-CAR-T therapyПодробнее

The benefits of glofitamab in R/R DLBCL post-CAR-T therapy